GSK, FDA and meningococcal

US FDA approves GSK's combo meningococcal vaccine
The U.S. Food and Drug Administration approved British drugmaker GSK's combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company said on Saturday.
FDA Approves More Broadly Protective Meningococcal Vaccine
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive meningococcal disease (IMD), according to a press release from GlaxoSmithKline (GSK).
GSK’s Penmenvy meningococcal vaccine gains FDA approval
The studies confirmed that the vaccine has a safety profile consistent with the licensed meningococcal vaccines of GSK. The integration of the MenABCWY vaccine into healthcare pra
GSK’s 5-in-1 meningococcal shot wins FDA approval
Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through 25 years old.
FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week
GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage recommendations on Feb. 26.
With new FDA approval, GSK joins Pfizer in the 5-in-1 meningococcal vaccine ring
Pfizer’s two-year run with the only 5-in-1 meningococcal vaccine on the U.S. market has come to an end. Now, GSK is ready to play catch-up after nabbing its own FDA approval.  | The company's Penmenvy combines components of its established MenB and MenACWY vaccines Bexsero and Menveo,
GSK reports FDA approves Penmenvy 5-in-1 meningococcal vaccine
GSK (GSK) plc announced that the Food and Drug Administration has approved Penmenvy for use in individuals aged 10 through 25 years. The
PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY
Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the opportunities ahead to help improve meningococcal vaccination coverage in the United States, especially for IMD caused by serogroup B.
FDA approves GSK’s pentavalent meningococcal vaccine
The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against five meningococcal serogroups, the company announced.The vaccine, branded as Penmenvy,
STAT19h
Pharmalittle: We’re reading about the impact of HHS firings, a GSK vaccine approval, and more
Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...
pharmaphorum1d
GSK gets ready for its next big vaccine launch
GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for ...